Table 2.
Characteristics of patients with rheumatoid arthritis (RA) with erosive and non-erosive disease
| RA erosive, n=12 | RA non-erosive, n=15 | p Value | |
|---|---|---|---|
| Age, years | 53 (24–82) | 54 (22–58) | 0.88 |
| Disease duration, months | 5 (1–10) | 4 (1–12) | 0.86 |
| DAS28 | 5.0 (2.9–6.6) | 5.9 (3.3–6.7) | 0.13 |
| ESR, mm/h | 37 (3–91) | 27 (7–76) | 0.67 |
| CRP, mg/litre | 9 (3–114) | 16 (3–133) | 0.62 |
| VAS, 0–100 | 27 (11–76) | 50 (25–98) | 0.12 |
| IgM-RF positive, % | 66 | 43 | 0.27 |
| ACPA positive, % | 44 | 50 | 0.80 |
| DMARD monotherapy | 9 | 8 | |
| ≥2 DMARDS | 3 | 5 | |
| MTX plus anti-TNFα | 0 | 2 |
Patients were classified as having rheumatoid arthritis (RA) based on 1987 American College of Rheumatology (ACR) criteria.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IgM-RF, immunoglobulin M rheumatoid factor; MTX, methotrexate; TNF, tumour necrosis factor; VAS, visual analogue scale of global disease activity.